4 results
Primary Objectives:• To compare progression free survival (PFS) as determined by blinded independent central review (BICR) and overall survival (OS) of nivolumab combined with ipilimumab to pemetrexed plus cisplatin or carboplatin regimen as first…
Primary Objective: To compare overall survival (OS) of subjects randomized to ipilimumab in addition toplatinum and etoposide (Arm A) to that of subjects randomized to placebo in addition to platinum andetoposide (Arm B) in subjects with newly…
To estimate the onset of analgesia of the oxycodone IR formulation OxyNorm Instant using an acute pain model in healthy volunteers.
To generate high quality empirical evidence for the effectiveness in terms of proportion of patients experiencing complications, quality of life and costs of initial non-operative treatment strategy (reserving appendectomies for those not responding…